Bruker Corporation

NasdaqGS:BRKR Stok Raporu

Piyasa değeri: US$6.7b

Bruker Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Bruker kazanç ve gelirin sırasıyla yıllık 103% ve 4.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 103.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

103.0%

Kazanç büyüme oranı

103.09%

EPS büyüme oranı

Life Sciences kazanç büyümesi17.5%
Gelir büyüme oranı4.6%
Gelecekteki özkaynak getirisi14.43%
Analist kapsamı

Good

Son güncelleme09 May 2026

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...

Recent updates

Analiz Güncellemesi • Apr 29

BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path

Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.
Analiz Güncellemesi • Apr 15

BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings

Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
Analiz Güncellemesi • Apr 01

BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E

Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.
Seeking Alpha • Mar 31

Bruker: A Better, Yet Speculative Proposition

Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking Alpha
Analiz Güncellemesi • Mar 18

BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E

Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.
Analiz Güncellemesi • Mar 03

BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E

Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.
Analiz Güncellemesi • Feb 17

BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions

Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.
Analiz Makalesi • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...
Analiz Güncellemesi • Feb 03

BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple

Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.
Analiz Güncellemesi • Jan 20

BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple

Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.
Analiz Güncellemesi • Jan 06

BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations

Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.
Analiz Güncellemesi • Dec 17

BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations

Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.
Analiz Güncellemesi • Dec 03

BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations

Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.
Analiz Makalesi • Nov 26

Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry

Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...
Analiz Güncellemesi • Nov 19

BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook

Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.
Analiz Güncellemesi • Nov 03

BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience

Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.
Analiz Makalesi • Aug 10

Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge

NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...
Analiz Güncellemesi • Aug 06

Renewed Biopharma Funding And Cost Savings Will Revitalize Markets

Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).
Analiz Makalesi • Jun 25

Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price

Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...
Analiz Makalesi • May 31

A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...
Analiz Makalesi • May 16

Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture

The market for Bruker Corporation's ( NASDAQ:BRKR ) shares didn't move much after it posted weak earnings recently. We...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:BRKR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20283,950N/A3064097
12/31/20273,74416127435012
12/31/20263,58812027235312
3/31/20263,459-3622140N/A
12/31/20253,437-2214134N/A
9/30/20253,439-24-1194N/A
6/30/20253,4438049166N/A
3/31/20253,44680175295N/A
12/31/20243,366113136251N/A
9/30/20243,241305157267N/A
6/30/20243,120352168273N/A
3/31/20243,001402181284N/A
12/31/20232,965427243350N/A
9/30/20232,818319206316N/A
6/30/20232,715319201342N/A
3/31/20232,621312149284N/A
12/31/20222,531297145274N/A
9/30/20222,506275119242N/A
6/30/20222,476274114196N/A
3/31/20222,458282176262N/A
12/31/20212,418277190282N/A
9/30/20212,362270254347N/A
6/30/20212,264238312405N/A
3/31/20212,118204304395N/A
12/31/20201,988158235332N/A
9/30/20201,960158169265N/A
6/30/20201,970165140235N/A
3/31/20202,035177141234N/A
12/31/20192,073197N/A213N/A
9/30/20192,026207N/A210N/A
6/30/20191,972189N/A185N/A
3/31/20191,925184N/A210N/A
12/31/20181,896180N/A240N/A
9/30/20181,87398N/A211N/A
6/30/20181,84292N/A219N/A
3/31/20181,81384N/A166N/A
12/31/20171,76679N/A154N/A
9/30/20171,706151N/A142N/A
6/30/20171,664161N/A142N/A
3/31/20171,621152N/A177N/A
12/31/20161,611154N/A131N/A
9/30/20161,619146N/A190N/A
6/30/20161,621111N/A208N/A
3/31/20161,646119N/A188N/A
12/31/20151,624102N/A229N/A
9/30/20151,65466N/A149N/A
6/30/20151,67760N/A108N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BRKR önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: BRKR önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: BRKR önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: BRKR şirketinin gelirinin (yıllık 4.6% ) US pazarından (yıllık 11.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BRKR şirketinin gelirinin (yıllık 4.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BRKR 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.4 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/11 02:10
Gün Sonu Hisse Fiyatı2026/05/11 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Bruker Corporation 29 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Luke SergottBarclays
Michael RyskinBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)